Exec Chat: Sequana Medical Pursues Dual Device-Drug Strategy For Fluid Overload

Speaking to Medtech Insight, Sequana Medical’s CEO discussed the company’s two technologies for combating fluid overload whilst explaining that, sometimes, chasing approval as a drug can be the best way to ensure easy market access.

Water and sodium: the two things Sequana Medical are developing technologies to remove • Source: Shutterstock

New drugs and devices appear to follow a similar path to market – an idea is formed, or a discovery is made, and then is developed into a product following regulatory approval.

But the differences between the drug and device regulatory and development pathways are significant, so companies typically focus on one...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D